Antiviral treatment options for HCV-infected patients with advanced kidney disease are limited because few clinical trials have tested the efficacy of antiviral drugs in this population. Now, a phase III trial of two pan-genotypic drugs demonstrates excellent viral clearance with minimal adverse events in HCV-infected patients with advanced kidney disease.
This is a preview of subscription content
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ladino, M., Pedraza, F. & Roth, D. Hepatitis C virus infection in chronic kidney disease. J. Am. Soc. Nephrol. 27, 2238–2246 (2016).
Fabrizi, F., Dixit, V. & Messa, P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J. Viral Hepat. 19, 601–617 (2012).
Molnar, M. Z. et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61, 1495–1502 (2015).
Goodkin, D. A. et al. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin. J. Am. Soc. Nephrol. 12, 287–297 (2017).
Gane, E. et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N. Engl. J. Med. 377, 1448–1455 (2017).
Saxena, V. et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 36, 807–816 (2016).
Roth, D. et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386, 1537–1545 (2015).
Pockros, P. J. et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150, 1590–1598 (2016).
Gane, E. et al. in AASLD The Liver Meeting abstract 935 (Boston, 2016).
Rodriguez, C. V. et al. in AASLD The Liver Meeting abstract 1946 (Boston, 2016).
M.L. declares no competing interests. D.R. is a consultant and is on the Scientific Advisory Boards for Merck & Co. and AbbVie.
About this article
Cite this article
Ladino, M., Roth, D. Treatment of HCV-infected patients with advanced kidney disease. Nat Rev Nephrol 14, 6–8 (2018). https://doi.org/10.1038/nrneph.2017.161